Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
- Details
- Category: Novo Nordisk
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.
Merck awarded Australian CRISPR nickase patent for foundational genome-editing technology
- Details
- Category: Merck Group
Merck, the vibrant science and technology company, today announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a significant step in increasing safety by driving specificity through a highly flexible and efficient approach to reduce off-target effects.
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF).
Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
- Details
- Category: Bayer
Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions.
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets.
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
- Details
- Category: Novartis
Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia.
More Pharma News ...
- Roche reports very strong performance in the first half of 2018
- Atacand to be divested to Cheplapharm in Europe
- Novartis renews drug donation of Egaten® (triclabendazole) until 2022
- FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
- Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers
- Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
- Amgen and MBC Biolabs announce winners of the Amgen Golden Ticket